Key result
Post-vaccine myocarditis is a rare, predominantly male condition typically occurring within 5 days of a second mRNA COVID-19 vaccine dose with an overwhelmingly mild, self-limiting course.
Answers are grounded in this paper and cite their sources.
This editorial outlines the immunopathological mechanisms and endorses a pragmatic 3-part clinical pathway for diagnosing, risk-stratifying, and selectively immunosuppressing patients with post-COVID-19 vaccine myocarditis.
mong the seemingly endless "unknownunknowns" that the COVID era has foisted on policy makers, public health, health care providers, researchers, and the public is the apparently novel cardiac disease identified in this issue of the Journal of the American Heart Association (JAHA) 1 as "myocarditis after COVID-19 vaccination," elsewhere as "postvaccine myocarditis," and perhaps in the future along the lines of "vaccine-triggered, selflimiting, acute autoimmune myocarditis." This potentially serious complication has been associated with serious harm, arguably most prominently through promotion of vaccine hesitancy, another complex mechanism underlying COVID19-mediated harm.
No takes yet. Share an insight, caveat, or question.
Mohiddin et al. (2022) conducted an editorial in Vaccine-triggered acute autoimmune myocarditis (post-COVID-19 vaccination myocarditis). COVID-19 mRNA vaccination was evaluated. Post-vaccine myocarditis is a rare, predominantly male condition typically occurring within 5 days of a second mRNA COVID-19 vaccine dose with an overwhelmingly mild, self-limiting course.
Synapse has enriched 10 related papers. Consider them for comparative context: